Documents and PDFs
The WFH Guidelines for the Management of Hemophilia: AAV Gene Therapy
The WFH Guidelines for the Management of Hemophilia: AAV Gene Therapy provide the first comprehensive, evidence-based recommendations to support the
Year: 2017
Language: English
This resource is also available in:
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment of hemophilia.
It discusses the factors that contribute to the quality, safety, and efficacy of hemophilia treatment products and, in particular, the provisions made for ensuring that these products are free of viruses. It covers well-established systems in the United States and the European Union that regulate and control therapeutic products for hemophilia.
For regulatory agencies in countries without established systems, this guide provides guidance for the development of procedures, and offers a model for the evaluation of products, to ensure the safety and quality of therapeutic products for hemophilia.
The WFH Guidelines for the Management of Hemophilia: AAV Gene Therapy provide the first comprehensive, evidence-based recommendations to support the
The 3rd edition has also been translated into the following languages, with permission from the WFH, by NMOs/Other Organizations: Georgian,
A 3ª edição do Manual de Laboratório da WFH é o guia definitivo para o diagnóstico preciso da hemofilia e
The World Federation of Hemophilia invited representatives from its national member organizations, national governments, healthcare providers, industry partners, and other
This video gives a quick introduction to ultra-long half-life (UHL) clotting factor replacement therapy. Learn more about different treatment options
The 3rd edition of the WFH laboratory Manual is the definitive how-to guide for the accurate diagnosis of hemophilia and